Navigation Links
VH1 Teams Up with Dr. Drew for 'Celebrity Rehab With Dr. Drew,' a Series Depicting the Process of Overcoming Addiction
Date:11/27/2007

e with substance issues to explore rehab as a viable option," said Michael Hirschorn, Executive Vice President, Original Programming and Production, VH1. "There is no one better than Dr. Drew to deal with this topic honestly while assisting people who truly need his expertise and guidance."

All but one of the patients completed an intensive 21-day round-the-clock program with both group and one-on-one therapies. After they completed the program, the patients were given the opportunity to continue their treatment in a sober living facility or treatment center for at least three months at VH1's expense.

While most people know Dr. Drew as the host of the syndicated radio show Loveline and the MTV show of the same name, Dr. Drew is a medical doctor on staff at Huntington Hospital, a board certified addictionologist and medical director of the chemical dependency unit at Las Encinas Hospital in Pasadena, where he has been treating addicts for over 20 years. Although he is an associate professor of clinical psychiatry at the KECK USC School of Medicine, he is not a psychologist or psychiatrist. His book, Cracked: Putting Broken Lives Together Again (Harper-Collins,) is all about what treating addicts is like from a caretaker's perspective. Dr. Drew co-authored the first academic study on celebrities and narcissism. The study was published in the Journal of Research in Personality (Elsevier) in September 2006, and is the first systematic, empirical scholarly study of celebrity personality.

"Celebrity Rehab With Dr. Drew" is executive produced by John Irwin and Damian Sullivan for Irwin Entertainment. Dr. Drew Pinsky and Howard Lapides are also executive producing. Michael Hirschorn, Jeff Olde, Jill Holmes, and Noah Pollack are executive producers for VH1.

VH1 connects viewers to the music, artists and pop culture that matter to them most with TV series, specials, live events, exclusive online content and public affairs initiatives. VH1 is availa
'/>"/>

SOURCE VH1
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
2. Figure Skater Peggy Fleming Teams with HealthSaver: Raise Healthy Children Through Active Parenting
3. Teamsters Applaud Passage of Legislation to Protect Workers From Diacetyl Exposure
4. Creating Effective Cross-Functional Teams for Pharmaceutical Commercialization Success
5. TeamStaff Receives A Letter of Reprimand From Nasdaq; No Further Action Contemplated
6. Natural Disaster Rescue Teams at Public Health Facilities Across the Country Learn from Katrina Failures
7. Figure Skater Peggy Fleming Teams With HealthSaver: Cook Your Way to a Healthy Diet
8. Riverside Partners Teams with Management to Acquire GEMCITY Engineering & Manufacturing
9. VIDEO from Medialink and General Mills: Ellen DeGeneres Teams Up with Pink for the Cure
10. WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA
11. Scrapblog(TM) Teams with March of Dimes to Tell Every Babys Story
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...he University of Texas Health Science Center at Ho...ce in Aging Studies (TEXAS), to promote geriatrics...million award from the Donald W. Reynolds Foundati...ll allow us to teach geriatric medicine principles...to practicing physicians. With the reach of Lyndon...
(Date:11/21/2008)...PRNewswire-FirstCall/ -- The Providence Service,C...Craig A. Norris, the Company,s,Chief Operating Of...f,Directors. Mr. Norris, appointment fills the v...en I. Geringer and returns the board to six member... the Board. , Mr. Norris, age 41, has been ...
(Date:11/21/2008)...ved effective against Lennox-Gastaut syndrome , ...w drug called Banzel (rufinamide) has been approve...f epilepsy called Lennox-Gastaut syndrome, the U.S..., The approval was based on results of a four-mo...o 30. Compared to patients who took a placebo, tho...
(Date:11/21/2008)...21 New research at Wes...eless, spitless tobacco product aimed at young adu... that RJ Reynolds, Camel Snus - touted as a social...surprisingly high levels of nicotine. , , "...snuff products," said Bruce Adkins of the state Di...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3
...earchers from the Johns Hopkins Department of had ...y in the heart after a heart attack. // The resea...called SPECT/CT, to successfully trace stem cells’... injected into the body to treat animal hearts dam...
...ple suffering from anorexia nervosa have the simil...d other emotional disorders. // The study was publ...l Psychiatry. Previous evidence has suggested that...nin (a brain chemical involved in communication be...
...ral tube defects are congenital deformities that a...ifida and anencephaly are the two most common form...s paralysis in spina bifida and fatal brain deform...t can be diagnosed by antenatal ultrasound, nothin...
... aortic valve in the heart is the valve that gover...ely the aorta, which supplies blood to various org...wing back inside the heart from the rest of the bo...heart depends on the proper functioning of the aor...
Other Medicine News:Health News:Percutaneous aortic valve replacement- a revolution in Cardiac Surgery 2
(Date:11/20/2008)...LE, Calif., Nov. 20 Bion... will present results from the Phase 1B,clinical ...tastatic breast,cancer, BZL101, at the Society fo...erence in Atlanta, Georgia. The Company,s oral pr... and will be presented as a part of the Best of th...
(Date:11/20/2008)...SO, Norway, November 20 The Scandi...arma has announced results of studies on its,lead...AC in Washington, DC,the studies showed that the...cteriocidal effect, significantly better towards k...ogenes than marketed gold standard drugs. In,addi...
(Date:11/19/2008)...ELLE, N.Y., Nov. 19 Biotech scient...es to toxicology research to better understand the...organ systems, reports Genetic Engineering & ...nterested in figuring out a new compound,s mechani...e toxicology technique, according to the November ...
(Date:11/18/2008)... Pa., Nov. 18 Arlington Medical Re...ligence for the pharmaceutical and diagnostic,ima...L Behring,s Privigen was,sold in the U.S. during ...,brand of intravenous immune globulin (IVIG) and w... a product created from the blood plasma of thousa...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Cardiome Reports First Quarter Results 19236 1Cardiome Reports First Quarter Results 19236 2Cardiome Reports First Quarter Results 19236 3Cardiome Reports First Quarter Results 19236 4Cardiome Reports First Quarter Results 19236 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 1Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 2Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 3Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 4Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 6Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 7Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 8Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 9Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 10Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 11Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 12Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 1Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 2Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 3Quality Lags at Safety Net Hospitals 19232 1Quality Lags at Safety Net Hospitals 19232 2Quality Lags at Safety Net Hospitals 19232 3
..., 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. ...elanoma vaccine clinical trial and data from the P... vaccine clinical trial will be,presented at the 2...3rd annual meeting in Chicago on June 1-5 2007. , ...cal and immunological responses in patients with m...
...e Patients Receiving Combination of,Bavituximab Pl...sponse or Stable Disease - , - 75% of Patients ...ine , ,Achieved Objective Tumor Response...Receiving Combination of Bavituximab Plus , ... Response - , - Trial Results Support Advanc...
Other Medicine Technology:IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 2IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 3IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 4IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 5IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 6Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 2Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 3Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 4Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 5
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003.
Athouritative, on the spot answers for acute care and consultations.
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
Medicine Products: